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Abstract
Protein kinases are critical drug targets for treating a large variety of human diseases. TypeIII kinase inhibitors have attracted increasing attention as highly selective therapeutics.
Thus, understanding the binding mechanism of existing type-III kinase inhibitors provides
useful insights into designing new type-III kinase inhibitors. In this work, we have systematically studied the binding mode of MEK-targeted type-III inhibitors using structural systems
pharmacology and molecular dynamics simulation. Our studies provide detailed sequence,
structure, interaction-fingerprint, pharmacophore and binding-site information on the binding
characteristics of MEK type-III kinase inhibitors. We hypothesize that the helix-folding activation loop is a hallmark allosteric binding site for type-III inhibitors. Subsequently, we
screened and predicted allosteric binding sites across the human kinome, suggesting other
kinases as potential targets suitable for type-III inhibitors.

Introduction
Kinases are phosphorylation enzymes that catalyze the transfer of phosphate groups from ATP
to specific substrates and are critical in most cellular life processes [1,2]. Abnormal kinase regulation, which leads to signal disruption and cell deregulation, is implicated in many diseases,
particularly cancers [3]. Thus, a number of kinase-targeted small molecule inhibitors have
been developed that are important in anti-cancer therapy [4]. Through July 2016, 30 small
molecule kinase inhibitors [5,6] have been approved by the US Food and Drug Administration
(FDA) for the treatment of cancers and other diseases (http://www.fda.gov/) and additional
more inhibitors are undergoing clinical trials [7,8].
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However, reported off-target toxicities and acquired-mutation resistance [9] require
kinase-targeted inhibitors of lower dose and higher specificity. Typically, three types of targeted kinase inhibitors, type-I, type-II and type-III, have been developed [10,11]. Type-I
inhibitors are ATP-competitive and occupy the ATP-binding binding pocket, a highly conserved kinase catalytic scaffold with strong binding affinity for ATP. Driven in part by the
increased number of diverse protein kinase structures, type-II and type-III inhibitors have
also been developed [12]. Type-II inhibitors bind to an extended binding pocket that
includes the ATP-binding pocket and the adjacent less-conserved allosteric site across the
DFG motif. Although type-II inhibitors occupy larger binding pockets than type-I inhibitors,
it has not followed that type-II inhibitors are more selective [13]. However, type-III inhibitors occupy highly specific allosteric sites which provides the opportunity to achieve higher
selectivity. To date type-III MEK inhibitors that inhibit MEK1 and/or MEK2 have attracted
substantial interest. Dozens of type-III MEK inhibitors have been developed for clinical
applications or as molecular probes [14]. Notably, two type-III MEK inhibitors (Trametinib
and Cobimetinib) have been approved by the FDA [15,16]. Besides the type-III MEK inhibitors, several type-III inhibitors for other kinases have been reported [17] including the
BCR-ABL inhibitors GNF2 and ABL001 [18], the pan-AKT inhibitor MK-2206 [19] and the
mutant-selective EGFR allosteric inhibitor EAI045 [20]. In summary, the evidence suggests
that type-III inhibitors provide a valuable approach [17,20]. For example, the type-III MEK
kinase inhibitor, Cobimetinib (IC50 0.9 nM), overcomes the resistance induced by the BRAF
V600E mutation seen in melanoma by inhibiting MEK, which is downstream of BRAF in the
BRAF/MEK/ERK pathway [16]. To date, however, there is no systematic means of identifying the preferred characteristics of specific type-III inhibitors [8]. Since existing type-III
kinase inhibitors mainly target MEK [17] by understanding the molecular characteristics of
type-III MEK inhibitors, the goal is to use that understanding to develop type-III inhibitors
more broadly across the human kinome.
In this work we have integrated the structural systems biology strategy and molecular
dynamics simulation methods to gain insights into type-III kinase inhibitors and their binding
modes with human protein kinases. The structural system biology strategy harnesses multiple
omics data resource to compare and discover the gene-level, protein-level and structure-level
information on protein-ligand interactions [21]. We have previously applied this strategy to
drug design and discovery for the human structural kinome (distinct from the work here) and
the Ebola virus proteome [5,22].
Further, with increased computing power and more efficient algorithms, molecular dynamics (MD) simulation is now becoming a routine tool for drug design, accounting for the reality
of a flexible target structure and flexible target-drug binding [23]. In this paper we performed
detailed MEK-inhibitor interactional fingerprint analysis using the aforementioned methods.
This was followed by two MD simulations up to 1.2 μs in an explicit water box to obtain
insights into the behavior of MEK as a flexible target, with and without the representative
ligand, Cobimetinib [24]. By comparing the structural trajectories between MEK with and
without ligand, we determined the structural flexibility and interaction network for type-III
inhibitor binding to MEK.
Finally, we studied the structural impact of point mutations, the MEK pharmacophore and
the mechanistic understanding of MEK-drug binding. Using these aggregate data as a template
we explored the whole human kinome to identify potential new opportunities for type-III
inhibition.
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Results
Binding modes of crystallized ligand-bound MEK complexes
We obtained the binding characteristics of ligand-bound MEK complexes as shown in Fig 1.
Fig 1a illustrates the alignment of the 29 catalytic kinase domains of MEK bound to the type
III inhibitors shown in the same allosteric binding site. We calculated the detailed interactions
between MEK and the ligand using the function-site interaction fingerprint (Fs-IFP) method
(Fig 1b). The highly conserved interactions between the respective ligands and MEK include
K97, L115, L118, V127, M143, C207DFGVS212, I215 and M219 (Fig 1b and 1c). These conserved interactions can be divided into three spatial regions.
The first region is the hydrophobic sub-pocket consisting of L115, L118, V127 and M143 as
shown in purple in Fig 1c. All interactions are apolar (Fig 1b). Correspondingly, all ligands
have hydrophobic groups that can be accommodated in the sub-pocket. For example, Cobimetinib has a 2-fluoro-4-iodoanilino fragment, as shown in purple in Fig 2 (4an2), which is a
well-known hydrophobic pocket binder and accommodates the hydrophobic sub-pocket with
hydrophobic contacts as shown in Fig 1c. Other ligands also have the same or similar fragments (Fig 2, the fragment in purple) so as to achieve the high binding affinity of the conserved
sub-pocket. Pharmacophore modeling, as shown in Fig 1d, also revealed similar patterns with
three common hydrophobic groups, H3, H4 and R7.
The second region is K97, an important catalytic residue, located at the roof of the binding
pocket (Fig 1c, yellow color). K97 has a conserved interaction with the oxygen atom O
(marked in Fig 2, dark blue color) of the respective ligands. The molecular moiety O is conserved, shown in the same position for other compounds in dark blue, either as an oxygen or
nitrogen atom (Fig 2, 3eqb and 3eqh). Pharmacophore modeling (Fig 1d) is consistent with
one donor-type hydrogen bond, D2.
The third region, consisting of C207DFGVS212, I215 and M219, forms a loop and a helix
that acts like an arm to accommodate the inhibitor in the kinase active site. DFG is directly
involved in kinase catalytic activity and is conserved across the human kinome. I215 and
M219 are located in the activation loop. Interestingly, in MEK the activation loop folds into a
short helix which forms the allosteric site. In most MEK-ligand structures, S212 has a strong
interaction with the corresponding ligand (Fig 1b, S212 column, red color) including an apolar and hydrogen-bond interaction. However, in the structures 1s9j, 3egg, 3oss, 4v04 and
4an3, S212 forms only a polar interaction with the corresponding ligand. This conserved
interaction is consistent with experiment which shows that S212 plays a key role in phosphorylation by RAF [16]. In this third region all active ligands have one atom (F, N or O.
such as F in Fig 2, 4an2, in red color) that interacts with the backbone of S212. Pharmacophore modeling (Fig 1d, H5 and R6) illustrates that all ligands have common features in
their interaction with S212.
Taken together, the aforementioned three regions make major contributions to ligand
binding in the allosteric pocket. Summarizing Fig 1d, the hydrophobic heads (H3, H4 and R7)
accommodate the hydrophobic sub-pocket and D2 and H5 interact with the roof amino acid
K97 and S212 of the loop, respectively. It is expected that an active MEK inhibitor would have
these chemical functional groups or similar. Furthermore, in 3D space, these atoms are spatially conserved, as shown by the triangles in Fig 2 for D2, H4 and H5, suggesting that the
design of MEK allosteric inhibitors should follow this pharmacophore. Similar conserved spatial requirements have been reported in the design of other allosteric inhibitors [20]. Of course,
besides the conserved pharmacophores, different inhibitors are subjected to specific interactions involving other amino acids to achieve selectivity, as shown in Fig 1b. Specifically, the
solvent exposed part of the inhibitor, shown in Fig 2 in green, can be substituted by different
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Fig 1. Binding characters of MEK-ligand complexes. a) All MEK-ligand complex structures aligned using SMAP. b) Encoding all MEK-ligand
interactions. Every row represents the MEK-ligand interaction fingerprint of one complex structure, and every column represents the interactions
between the same amino acid in space and the bound ligand in different complex structures. Different colors represent the different types of fingerprint
interactions: yellow, no interaction; blue, apolar interaction; red, apolar interaction + hydrogen bond interaction (protein as donor); deep red, hydrogen
bond interaction (protein as donor); pink, polar interaction+ aromatic interaction; and grey, apolar interaction + hydrogen bond interaction (protein as
acceptor). c) Spatial representation of MEK-ligand interactions. d) Pharmacophore modeling: H, hydrophobic group; R, aromatic ring; D, hydrogenbond donor.
https://doi.org/10.1371/journal.pone.0179936.g001

chemical group or atoms. The pharmacophore has no common features for the solvent
exposed part (Fig 1d). These differences reflect different levels of inhibition as illustrated by
Rice and coworkers found in the structure-activity relationships while optimizing a series of
compounds leading to Cobimetinib [15]. Based on the co-crystal complex structure with Cobimetinib and ACP, an ATP analogue, shown in S1 Fig, the solvent exposed parts of the inhibitor
are right next to the γ-phosphate of ATP and an interaction between them is formed. This
interaction disturbs the functional conformation of the γ-phosphate of ATP and the substrate
being phosphorylated, reducing MEK’s enzymatic activity.
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Fig 2. Ligands from the 29 MEK-ligand complex structures. The triangles highlight the conserved structure-activity relationships (SARs) that
characterize the MEK Type-III inhibitors in 3D space.
https://doi.org/10.1371/journal.pone.0179936.g002

MEK structural flexibility and insights into the binding mechanism
Beyond studying the binding modes from released PDB structures for MEK, we considered
how type-III inhibitors influence MEK structural flexibility. We performed two 0.6 μs MD
simulations for MEK kinase with and without the inhibitor bound. The overall Cα-RMSDs of
the apo and holo structures are similar (S2 Fig). However, individual Cα-atom fluctuations
show significant differences, especially in the ligand-bound regions (Fig 3a), where we compared MEK structural flexibility before and after binding using the two last 0.5 μs equilibrated
MD trajectories. For apo MEK the flexibility change mainly comes from the P-loop, the activation loop and the C-terminal lobe as shown in Fig 3a. The corresponding collective motion as
inferred from the first principal component of PCA is shown in Fig 3b. As a comparison, in
the MEK-Cobimetinib complex, the main fluctuations come from the parts of the C-helix, the
C-terminal part of the activation loop and the C-terminal lobe (Fig 3a). The obvious difference
before and after binding inhibitor is that the collective motions of the P-loop and activation
loop have undergone a substantial reduction and the flexibility of the C-helix has significantly
increased in the MEK-Cobimetinib complex compared to apo MEK. Similar to other kinases,
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Fig 3. RMSF profiles and PCA projection. a) The RMSF profiles from the last 0.5 μm equilibrated MD trajectories of MEK and the MEK-Cobimetinib
complex, respectively. Some secondary structure elements are shown on the abscissa. b) and c) The Cα-atom projection along the first principal
component. The displacements are shown as color-coded tubes from blue (small displacement) to orange (large displacement) for (b) MEK and (c) the
MEK-Cobimetinib complex.
https://doi.org/10.1371/journal.pone.0179936.g003

the P-loop contributes to conformational flexibility and plays an important role in binding
and recognizing phosphoryl moieties [25]. Moreover, this flexible P-loop motif, along with
other beta-sheets and helixes, generally form a pocket into which the phosphate groups can
insert [26,27]. Like the P-loop, the activation loop shows a similar change in flexibility before
and after Cobimetinib binding. Like other kinases, MEK Glu114 within the C-Helix, Lys97
and the DFG peptide form the ATP catalytic center, where the salt-bridge between Glu114 and
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Fig 4. Two conserved interatomic interactions between MEK and the ligand. (a) Interatomic distances for every conformation from the MD
trajectory; (b) The probability distribution of interatomic distances.
https://doi.org/10.1371/journal.pone.0179936.g004

Lys97 is needed for catalysis. Upon Cobimetinib binding to MEK, the salt-bridge interaction is
broken. It may have significant effect on the function of the C-helix [8,28]. In addition, the
activation loop forms a short helix in MEK, whereas in most kinases the activation loop is a
flexible loop. One hypothesis that follows is that the short helix is important in forming the
allosteric binding pocket that accommodates a type-III inhibitor and a necessary consideration
in the design of new type-III inhibitors [29].

Conserved interactions with inhibitors from S212 and K97
As aforementioned, the inhibitors derived from PDB MEK structures have a similar core and
common functional groups forming a conserved spatial triangular arrangement (Fig 2). Correspondingly, in the MEK-Cobimetinib MD trajectories the conserved interactions between
MEK and respective inhibitors were evaluated (Fig 3c). Two key interactions between S212,
K97 and Cobimetinib are highlighted here (Fig 4). The interaction between the backbone
nitrogen atom of S212 and the F atom of the inhibitor is shown in red. From the probability
distribution (Fig 4b) the center of the peak is at 3.1 Å, which suggests that a hydrogen bond
interaction is conserved at all times to maintain the binding affinity and restrain the flexible
movement of S212, thereby hindering MEK phosphorylation by RAF. This observed hydrogen
bond interaction is in agreement with reported experimental results [16].
The O atom (Fig 2, 4an2) is another conserved polar atom contributing to the effective
binding. As shown in Fig 4 in green, the position of the peak in the probability distribution is
at approximately 3.0 Å, which agrees with the distance found in released crystal structures, for
example, 4lmn [15,16]. This distance suggests that there is a strong hydrogen-bond interaction
between O of the ligand and the ε-amino group of the lysine (K97), which contributes to the
catalytic center [30]. This hydrogen-bond interaction replaces the salt-bridge interaction
between the ε-amino group of Lys97 and the Glu114 of the C-Helix. Importantly, blocking the
salt-bridge interaction results in an inactive state [31] and increased flexibility of the C-Helix.
The O atom of Cobimetinib, the ε-amino group of Lys97 and the carboxyl group of Asp208,
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part of DFG, form the pseudo catalytic center and deactivate kinase activity in the MEK/ERK
pathway [32]. For other ligands (Fig 2), there is the same oxygen atom or similar nitrogen as
O , which should optionally be retained in future drug design studies.

Ranking similar binding sites to MEK using SMAP across the structural
kinome
To determine all other potential human protein kinases potentially suitable for type-III inhibition, MEK-similar binding pockets screening was performed across the human structural
kinome using SMAP [33–35]. Using the SMAP threshold of more than 55% similarity, three
crystal structures with binding pockets similar to MEK were found (pdb ids 2yix, 4pp7 and
4wo5). One structure is a P38α kinase [36] and two are BRAF kinases [2]. All three structures
contain a small helix within the activation loop. We aligned the sequences of MEK, P38α and
BRAF with particular attention to the activation loop. The sequence similarity is not high (S3
Fig; the activation loops are marked with a rectangle). These results lead us to hypothesize that
kinases with similar secondary structures in their activation loops have the potential to be
inhibited by type-III inhibitors, even though their global sequences do not have high similarity
with MEK. Ohren et. al. [29] have also suggested that the helix in the activation loop provides
structural insight into designing type-III inhibitors. This then begs the question, what other
human protein kinases can potentially form a helix in the activation loop?

Predicting helix containing activation loops across the human kinome
We predicted the secondary structure of the activation loop of all human protein kinases to
rank the similarity to the MEK activation loop helix that we suggest is critical for the binding
pose of the type-III inhibitor [37]. Based on amino acid sequences of all human protein
kinases, we determined the top 15 kinases that have a potential helix within the activation loop
[8] (Fig 5 and Table 1). The top 15 kinases are mostly located within the STE group which
forms the MAPK cascade. In terms of sequence, their activation loops don’t have high similarity to MEK, yet in terms of secondary structure prediction the activation loops of the 15
kinases may contain a helix. Among them MAP2K4 has been validated by a newly released Xray structure (pdb id 3alo) [38], in which the crystallized activation loop is shown to contain a
helix. If this helix is found in subsequent structures it will be important to consider it in future
type-III inhibitor design, partculalrly for the 15 protein kinase targets identified here.

Conclusions
Recently approved FDA type-III allosteric protein kinase inhibitors prompted us to consider
more efficient and lower-dose kinase inhibitors. Study of the type-III inhibitor-bound binding
site provides structural insights into the design of new allosteric inhibitors. Here we study the
characteristics of the MEK binding site, the chemical nature of the inhibitors that bind MEK,
and the dynamic characteristics and nature of the interaction between protein and inhibitor
from MD simulation. Further, based on all 3D kinase structures, we screened for potential allosteric inhibitor-bound binding sites. This revealed that the binding sites of BRAF and P38α
were similar to MEK. Finally, based on the distinctive helix character of the MEK activation
loop [37] we identified 15 kinases which potentially contain the allosteric site needed to
accommodate type-III inhibitors. In summary, our in silico analysis furthers our understanding of allosteric protein kinase inhibitors and forms a framework for allosteric-site prediction
that can be potentially tested by experiment.
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Fig 5. The phylogenetic distribution of the top 15 human protein kinases where a helix was predicted in the activation loop. The figure was
generated using TREEspot (www.discoverx.com).
https://doi.org/10.1371/journal.pone.0179936.g005

Methods
Functional site interaction fingerprint
Functional site interaction fingerprint (Fs-IFP) is a method to determine the functional site
binding characteristics and to compare binding sites on a proteome scale [5]. Here we use Fs-
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Table 1. Top 15 kinases predicted with high confidence to have a helix at part of the activation loop.
Kinases
TK_JakB__Domain2_JAK3
STE_STE20_KHS_HPK1

Sequences at Activation loop

Predicted secondary structure

Confidence of prediction

DPGVSPAVLSLEMLTDRIPWVA

- - - - -HHHHHHHHH- - - - - - -

9998535655555404886148

DFGISAQIGATLARRLSFIGTP

- - - - - -HHHHHHHHH- - - - - -

9998651226787750368999

AGC_MAST__MAST3

DFGLSKIGLMSMATNLYEGHIE

- - - - - -HHHHHHHHHHH- - - -

9998601144567776216899

STE_STE20_MSN_ZC1_HGK

DFGVSAQLDRTVGRRNTFIGTP

- - - -HHHHHHHHHH- - - - - - -

9963576888764136316899

STE_STE20_MSN_ZC2_TNIK

DFGVSAQLDRTVGRRNTFIGTP

- - - -HHHHHHHHHH- - - - - - -

9963576888764136316899

STE_STE20_MSN_ZC3_MINK

DFGVSAQLDRTVGRRNTFIGTP

- - - -HHHHHHHHHH- - - - - - -

9963576888764136316899

DFGVAAKITATIAKRKSFIGTP

- - - -HHHHHHHHHHH- - - - - -

9965313789999811125899

AGC_MAST__MAST1

DFGLSKMGLMSLTTNLYEGHIE

- - - - -HHHHHHHHHHHH- - - -

9984235488888776425589

STE_STE7__MAP2K3

DFGISGYLVDSVAKTMDAGCKP

- - - -HHHHHHHHHHH- - - - - -

9998146789999832058999

STE_STE7__MAP2K6

DFGISGYLVDSVAKTIDAGCKP

- - - -HHHHHHHHHHH- - - - - -

9998146789999832058999

AGC_MAST__MAST2

DFGLSKIGLMSLTTNLYEGHIE

- - - - -HHHHHHHHHHHH- - - -

9984235488888887515589

STE_STE20_KHS_KHS2

STE_STE20_KHS_KHS1

DFGVSAQITATIAKRKSFIGTP

- - - -HHHHHHHHHHH- - - - - -

9983799999999803213999

STE_STE7__MAP2K4

DFGISGQLVDSIAKTRDAGCRP

- - - - -HHHHHHHHHH- - - - - -

9987278899999823378999

STE_STE7__MAP2K5

DFGVSTQLVNSIAKTYVGTNAY

- - - -HHHHHHHHHHHH- - - - -

9941799999999851688999

Other_NRBP__NRBP1

VAPDTINNHVKTCREEQKNLHF

- - - - -HHHHHHHHHHH- - - - -

9966457699999987058999

https://doi.org/10.1371/journal.pone.0179936.t001

IFP to reveal the binding characteristics of the MEK-inhibitor complex for all released MEK
structures from the Protein Data Bank (PDB) [39]. In brief, firstly we downloaded all available
MEK structures from the PDB; 35 MEK1 structures and 1 MEK2 structure (PDB id 1s9i). The
29 ligand-bound MEK structures formed the MEK structure dataset. We aligned all the binding sites of these ligand-bound structures using SMAP [33–35] and encoded the Fs-IFP as published in an earlier paper [5] using the Pyplif software [40]. Because MEK1 and MEK2 have
high sequence identity in their respective kinase domains and their sequence identity is 100%
in the allosteric binding site [29,41], in this paper, all residue numbering is relative to the
MEK1 sequence. The end result of Fs-IFP calculations for each structure is a one-dimensional
bit representation of a variety of interactions between every involved amino acid and the
ligand.

Pharmacophore modeling
Pharmacophore modeling was performed using Maestro from Schrodinger release 2016.02
[42]. Using the MEK structure dataset we found IC50 data for 19 entries (S1 Table). The pharmacophore model was trained using the ligands with an IC50 of less than 10 nM.

MD simulation
Two MD simulations were performed with starting conformations taken from the PDB: pdb
id 4an2 for the MEK-Cobimetinib complex; and pdb id 3zls for the MEK apo structure. Both
initial conformations were prepared for MD simulation using the ACEMD protocol [43]. The
protonation states of both systems were assigned a pH of 7.0, similar to the cellular environment. Then every His state and every disulfide bond were checked to make sure they conformed to a pH of 7.0. The systems were solvated in a rectangular water box with at least a 12Å
shell buffer from any-solute atoms. Charged ions were added to ensure an ionic strength of
0.20 M and electroneutrality. The CHARMM27 force field [44,45], CHARMM general force
field [46] and TIP3P force field were used for the kinase, ligand, and water molecules, respectively. Both simulations were relaxed with the standard MD protocol; 2ps minimization, 100ps
for NVT, 1ns for NPT with heavy-atom constraints and 1ns for NPT without any constraints.
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Subsequently, 0.6 μs MD simulations were performed. In both MD simulations all bonds were
constrained using SHAKE and the integration time step was 4 fs. The temperature bath used
the Langevin method, and 1atm pressure was maintained using the Berendsen method. Both
simulations were carried out using the ACEMD software [43] on the NIH high-performance
Biowulf cluster (https://hpc.nih.gov/). The MD results were analyzed using the conformations
during the last 0.5 μs MD trajectory. The analysis of MD trajectories, including Root Mean
Square Deviation (RMSD), Root Mean Square Fluctuation (RMSF) and Principal Component
Analysis (PCA), were performed with the Wordom tool [47].

Screening for similar binding pockets across the human structural
kinome
Approximately three thousands protein kinase structures have been solved by X-ray and NMR
methods. 2797 of these kinase structures included the catalytic domain and formed the human
structural kinome [5]. We then used the MEK-Cobimetinib complex (PDB id 4lmn) as a template to rank similar binding sites from the human structural kinome by performing a one-toall comparison using SMAP [33–35]. The top-ranked binding sites with p-values < 0.05 were
retained for further analysis.

Secondary structure prediction
Determining type-III inhibitors needs to be validated, not only by biological activity assay, but
also through analysis of an appropriate crystal structure [8]. Unfortunately, the type-III binding pocket is often not present in the crystal structure when there is no specific type-III inhibitor co-crystalized [8]. To obtain the MEK-similar allosteric site in such kinases, we predicted
the MEK-like secondary structure of the activation loop to establish the binding pose of the
type-III inhibitor [37]. We used a protein secondary structure prediction server Jpred4 [48] for
the task. First, the 516 kinase domain sequences for the eukaryotic protein kinase superfamily
were downloaded at kinase.com and were aligned using the cluster omega software [49]. Then,
from the alignment, the amino acid sequence of the activation loop for every kinase was
extracted with an additional 11 N-terminal and 11 C-terminal residues adjoining the DFG segments. Finally, the activation loop structure was predicted using the JPred RESTful API (v1.5)
[48] with default parameters.

Supporting information
S1 Fig. ACP-Cobimetinib-MEK co-crystal structure (pdb id 4an2). a) Cartoon model. b) 2D
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